RESUMEN

Because of the relatively low incidence of TEs in children, the diagnostic and therapeutic approaches used are largely extrapolated from guidelines for adults. Features that differ in children compared with adults include underlying disorders, high incidence of CVL-related DVT in the upper venous system, and response to SH, warfarin, and thrombolytic agents. There is a paucity of information on the risk/benefit ratio of the therapeutic interventions and long-term outcome. Clinical trials are urgently needed to clarify optimal management for pediatric patients with TEs.

Asunto(s)

Fibrinolíticos/uso terapéutico , Tromboembolia/tratamiento farmacológico , Terapia Trombolítica , Causalidad , Niño , Humanos , Guías de Práctica Clínica como Asunto , Tromboembolia/epidemiología